New anti-CD20 Mab Obinutuzumab just delivered positive results in its phase 2 study in lupus nephritis. We need to know more! #EULAR2019 https://t.co/Bx9OdmEtpy
Links:
Roche - Roche’s Gazyva (obinutuzumab) delivers positive topline results for pha…
https://www.roche.com/de/investors/updates/inv-update-2019-06-11c.htm
Jun-13-2019
